Rebetron Pediatric ClinicalTrials

• Phase I Dose Finding Study (Complete)

  • 48 weeks treatment, 24 weeks follow up
  • Intron A 3 MIU/m2 TIW & Rebetol 8,12,15 mg/kg/day
    • Dose of 15mg/kg/day selected for phase III
  • 61 children age 5 to 16 enrolled
    • 57 naïve/4 relapse

• Phase III Open Label Study (Ongoing)

  • 48 weeks treatment, 24 weeks follow up
  • Intron A 3 MIU/m2 TIW & Rebetol 15 mg/kg/day
  • 105 children age 3 to 16 enrolled
    • naïve only

Previous slide

Next slide

Back to first slide

View graphic version